Swiss industry body says US tariffs on pharmaceuticals will harm patients

100% tariffs proposed by U.S. President Donald Trump on the pharmaceutical industry; Switzerland's Interpharma warned this would threaten global production, disrupt supply chains and ultimately harm patients. The policy could materially raise costs, create supply shortages and put downside pressure on pharma sector valuations and cross-border manufacturing. Monitor policy developments and company exposure to U.S. import/tariff risk for portfolio positioning.

Analysis

100% tariffs proposed by U.S. President Donald Trump on the pharmaceutical industry; Switzerland's Interpharma warned this would threaten global production, disrupt supply chains and ultimately harm patients. The policy could materially raise costs, create supply shortages and put downside pressure on pharma sector valuations and cross-border manufacturing. Monitor policy developments and company exposure to U.S. import/tariff risk for portfolio positioning.